Hosted on MSN

Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years and above with moderate to severe hidradenitis ...
WebMD

Cosentyx: FDA Approves Biologic Under-the-Skin Shot for Teens With Moderate-to-Severe Hidradenitis Suppurativa

What Is Cosentyx, and Why Does It Matter? Cosentyx (secukinumab) is a fully human biologic medicine that targets and blocks interleukin‑17A (IL‑17A), a naturally occurring protein in the body that ...
Hosted on MSN

FDA approves NVS' Cosentyx in hidradenitis suppurativa for adolescents

Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the drug for treating pediatric patients 12 years and older with moderate to ...